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Abstract
Background: Desmoid tumors (DTs) are non-metastatic, locally aggressive neoplasms with high postoperative
recurrence rates. The pancreas is an extremely rare location for DTs. The local control of DTs is challenging. Surgery
and radiotherapy are currently the principal treatment modalities for DTs; however, some resections might not be
radical, and radiotherapy has several drawbacks. Therefore, many studies have been focusing on the molecular
pathways involved in DTs in order to develop molecular-targeted therapies or chemotherapy. Cyclooxygenase-2
(COX-2) has been demonstrated to play a role in the growth of DTs, and the pharmacologic blockade of COX
resulted in decreased cell proliferation in desmoid cell cultures in vitro.
Case presentation: Herein, we report a 57-year-old woman who presented with recurrent epigastric pain and
weight loss. An abdominal computed tomography scan showed an approximately 10-cm mass over the pancreatic
head region and dilatation of the pancreatic duct. Tumor biopsy and bypass surgery were performed. A DT was
confirmed on pathologic analysis. After resection, we prescribed treatment with the COX-2 inhibitor celecoxib. The
patient showed complete remission and there was no local recurrence or distant metastasis within the 24-month
follow-up period.
Conclusions: The outcome of this case study is encouraging, and long-term follow-up studies are required to
establish the effect of treatment with celecoxib on the prognosis of DTs.
Keywords: Desmoid tumor, Aggressive fibromatosis, Pancreatic head, Non-steroidal anti-inflammatory drugs,
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Background
A desmoid tumor (DT), also known as aggressive fibro-
matosis, is a rare soft tissue neoplasm. Patients with a
history of familial adenomatous polyposis, surgery, or
pregnancy show higher incidence rates of DT. Although
this type of tumor has a benign histology, it is locally in-
vasive. Intra-abdominal DT has a low incidence rate,
and DTs of pancreatic origin are rare. The treatment of
these rare tumors is challenging because of their poten-
tial for recurrence.
Resection with negative surgical margins is the most
successful treatment modality for DTs [1]. For patients
who refuse surgery or are not surgical candidates, radio-
therapy and medical therapy might be considered.
Herein, we report a 57-year-old woman who developed
DT at a rare location. A cystic and solid mixed lesion
was noted at the pancreatic head, and the final patho-
logic analysis indicated DT. The patient received only
medical therapy after the operation and achieved
complete remission.
Case presentation
A 57-year-old woman had underlying systemic iron defi-
ciency anemia. She presented to our outpatient clinic
with abdominal pain in March 2013. Panendoscopy and
colonoscopy were performed and no organic lesions
were detected in the upper and lower GI tract, and only
gastritis was noted. However, the abdominal discomfort
could not be eliminated and it worsened. Because of
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progressive abdominal pain, the patient was transferred
to the emergence department after 1 week. Abdominal
computed tomography (CT) (Fig. 1) revealed a marked,
approximately 10-cm mass in the pancreatic head. The
pancreatic head tumor was initially diagnosed and she
was then admitted for further examination.
During hospitalization, laboratory analysis did not show
hyperbilirubinemia and elevated amylase or lipase levels.
The levels of tumor markers including carcinoembryonic
antigen, carbohydrate antigen 19-9, and carbohydrate anti-
gen 125 were within normal limits. CT-guided aspiration
of the cystic component was performed, and cytological
analysis showed only some macrophages. We performed
surgical exploration on March 22, 2013.
During the operation, we found that the lesion was
approximately 10 cm in size with cystic and solid com-
ponents (Fig. 2). The tumor appeared to originate from
the pancreatic head and presented as a cystic hematoma
protruding downward into the mesocolon. We per-
formed partial cystectomy for hematoma evacuation,
and tumor tissue was obtained from the pancreatic
head for pathologic analysis. Examination of frozen
tissue section did not indicate any malignancy. Finally,
gastrojejunostomy bypass was performed without rad-
ical resection of the tumor. The patient showed good
postoperative recovery. The final pathologic analysis
confirmed the DT diagnosis and immunohistochemical
staining showed focal positivity for smooth muscle
actin and desmin but negativity for Mdm2, CDK4, and
CD34. The tumor showed strong positivity for beta-
catenin (Fig. 3).
The patient received one 200-mg tablet daily of the
non-steroidal anti-inflammatory drug (NSAID) celecoxib
for half a year. We obtained a follow-up abdominal CT
Fig. 1 Cystic part (1) and solid part (2) of the pancreatic head tumor
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scan in October 2013 after 6 months of celecoxib treat-
ment. The CT images showed a marked regression of the
existing pancreatic head mass and complete disappearance
of the cystic lesion. Therefore, the dose was modified from
one tablet daily to one tablet every other day with the
same dose of celecoxib starting from the date of the 6-
month follow-up until now. The abdominal CT scan ob-
tained at the 18-month follow-up in September 2014
showed no local recurrence (Fig. 4). There is no side effect
noted by the patient in the period of celecoxib treatment.
The patient is still receiving celecoxib treatment for the
control DT.
Discussion
DT originates from the abnormal proliferation of myofi-
broblasts. It is a very rare disease and presents with a
benign pathology; however, it exhibits local invasiveness
indicating clinical malignancy. The DT location can be
Fig. 2 The tumor (1) was noted from the pancreas and T-colon (2) was just above the tumor with mesocolon compressed. Although the mass
effect of tumor made the patient abdominal pain, bile duct was not compressed to cause obstructive jaundice and gallbladder (3) was
not distended
Fig. 3 Pathology showed positive staining for SMA, desmin, and beta-catenin. Desmoid tumor was confirmed in final diagnosis
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classified as extra-abdominal, abdominal, or intra-
abdominal. Genetic screening for defects showed that
mutations in the FAP gene were a risk factor that was
more frequently associated with intra-abdominal DT
[2]. Other studies showed that intra-abdominal DT fre-
quently had pelvic and mesenteric origins. DTs originating
from pancreas are very rare. To date, only 12 cases of
pancreatic DT have been reported [3–13]. Among these
articles, only three of them reported DTs that originated
in the pancreatic head, and all patients underwent tumor
resection [11–13]. The present case is the fourth case of
DT originating from the pancreatic head; however, it is
the only case treated by medication and achieved com-
pleted remission.
The clinical presentation of most patients with DT is
usually asymptomatic and otherwise presents non-
specific abdominal pain. DT diagnosis could not be con-
firmed via laboratory analysis or radiological images.
Therefore, the definitive diagnosis of DT could only be
based on histological and immunohistochemical findings
[14]. In present case, DT diagnosis was confirmed by the
final immunohistochemistry staining that showed strong
positivity for beta-catenin and focal positivity for smooth
muscle actin and desmin.
The current first-line treatment for DT is complete
resection with free margins. Sometimes, performing resec-
tion with wide, free margins for the prevention of tumor
recurrence is difficult because of the locally invasive be-
havior of the tumor. Chemotherapy, molecular-targeted
therapy, and radiotherapy are considered in cases with
high surgical risk. Another case that was successfully
treated with NSAIDs was previously reported [15].
Further analysis showed the stabilization of the beta-
catenin protein in DT caused by mutation in either the
APC or beta-catenin gene [16]. If mutated, beta-catenin
accumulates in the cell and activates the T cell factor,
which triggers the transcription of target genes including
COX-2 [17]. Therefore, an elevated COX-2 protein level
was observed in DT; COX-2 partially regulates prolifera-
tion through beta-catenin stabilization [18]. Therefore,
the degradation of this protein or reduction of the
nuclear accumulation of beta-catenin might decrease
tumor growth. A molecular model suggests an inter-
action between NSAIDs and beta-catenin. However, the
mechanism of beta-catenin inhibition by NSAIDs has
not yet been elucidated.
In the present case, the patient achieved complete re-
mission on treatment with a COX-2 inhibitor, celecoxib.
The initial plan was to treat the patient with tamoxifen;
however, owing to its side effect, we did not proceed
with this treatment option. At the end of the 2-year
follow-up, the patient showed no tumor recurrence with
maintenance therapy using celecoxib.
Tanaka et al. [15] reported that a patient who received
etodolac, another COX-2 inhibitor, only achieved partial
remission. NSAIDs indeed have a cytoreductive effect on
DTs. However, different types of NSAIDs appear to have
different efficacies in DT size reduction.
Although resection is the only radical treatment option
for DT according to the current consensus, medical therapy
also has an important role in the treatment of patients with
comorbidities or in those where resection is contraindi-
cated. Chemotherapy has a relatively high complication rate
for patients, and the results of radiotherapy treatment were
not optimistic. Therefore, NSAIDs offer another treatment
option for DT with fewer side effects. However, additional
clinical trials and molecular analyses should be performed
to test the effect of NSAIDs in the treatment of DTs.
Fig. 4 Follow-up CT in 18 months later showed marked regression of pancreatic desmoid tumor under celecoxib treatment
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Conclusions
Complete resection was reported as the first-line treat-
ment choice in the reviewed case reports. However, in this
case, single medical therapy using COX-2 inhibitor had
excellent treatment effects on sporadic and non-FAP-
associated DT. The details of the mechanisms should fur-
ther be investigated and the efficacies of different NSAIDs
should be established.
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